Patent · US Active

Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors

US10167290B2 · kind B2 · utility

1Cited by

18References

5Claims

0Family size

Assignee

Signal Pharmaceuticals, LLC · US

Inventors

Jan Elsner · Solana Beach, US
Roy L. Harris · San Diego, US
Branden Lee · Encinitas, US
Deborah Mortensen · San Diego, US
Garrick Packard · San Diego, US
Patrick Papa · San Diego, US
Jason Parnes · San Diego, US
Sophie Perrin-Ninkovic · Carlsbad, US
Jennifer Riggs · Irvine, US
John Sapienza · Chula Vista, US
Graziella I. Shevlin · San Diego, US
Lida Tehrani · San Diego, US
Jingjing Zhao · San Diego, US

Key dates

Filing date	Aug 18, 2017
Grant date	Jan 1, 2019
Priority date	—
Expiry date	Aug 18, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are methods for the preparation of substituted pyrazino[2,3-b]pyrazines of the formula (II): the method comprising contacting a compound of formula (VI): with R1—Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R3, Y, the palladium catalyst and the base are as defined herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.